Location: DIBIT1 A2, Floor 4, Room 23b
Postdoc fellow, Age related diseases Unit
Enrico obtained his master degree in Biotechnology at Università Vita-Salute San Raffaele, after an internship in the Biomolecular Mass Spectrometry Lab directed by Dr. Angela Bachi in 2009. During this experience he specialized himself in proteomics and he identified serum biomarkers able to predict patient response to EGFR inhibitor in non-small cell lung cancer (Milan et al., 2012).
In 2014, he received a PhD in Molecular Medicine at Università Vita- Salute San Raffaele in the lab of Dr. Simone Cenci investigating the role of autophagy in multiple myeloma (Milan et al. 2015). During these years he characterized the functions of the autophagic receptor of ubiquitinated proteins p62/SQSTM1 in multiple myeloma through an extensive and unbiased proteomic analysis of its interactors.
In 2015, he was visiting postdoctoral fellow in Prof. Jorge Moscat Lab at Sanford Burnham Prebys Medical Discovery Center, La Jolla CA.
He was awarded by international funding agencies with the Multiple Myeloma Research Foundation (MMRF) Junior Research Award 2016 and the International Myeloma Foundation (IMF) Brian D. Novis Research grant 2019.
As principal investigator, he characterized the biological role and the related molecular circuits of multiple myeloma tumor suppressor FAM46C in regulating antibody secretion (Fucci et al., 2020).
This opened new lines of research focused on investigating new molecular pathway impacting on plasma cell and multiple myeloma proteostasis, antibody production and drug sensitivity.
His research activity is actually supported by Fondazione Cariplo (Ricerca Biomedica Condotta da Giovani Ricercatori) e Ministero della Sanità (Ricerca Giovani Ricercatori 2018 and 2019).
Total Publications: 14 h-index: 10 (Scopus Author ID: 55314279400; ORCID: 0000-0003-3094-4275)
Fucci C, Resnati M, Riva E, Perini T, Ruggieri E, Orfanelli U, Paradiso F, Cremasco F, Raimondi A, Pasqualetto E, Nuvolone M, Rampoldi L, Cenci S, Milan E. The interaction of the tumor suppressor FAM46C with p62 and FNDC3 proteins integrates protein and secretory homeostasis. Cell Reports in press.
Battista RA, Resnati M, Facchi C, Ruggieri E, Cremasco F, Paradiso F, Orfanelli U, Giordano L, Bussi M, Cenci S, Milan E. Autophagy mediates epithelial cancer chemoresistance by reducing p62/SQSTM1 accumulation. PLOS ONE. 2018 Aug 1;13(8):e0201621. doi: 10.1371/journal.pone.0201621.
Milan E, Perini T, Resnati M, Orfanelli U, Oliva L, Raimondi A, Cascio P, Bachi A, Marcatti M, Ciceri F & Cenci S. A Plastic p62-Dependent Autophagic Reserve Maintains Proteostasis and Determines Proteasome Inhibitor Susceptibility in Multiple Myeloma Cells. Autophagy 2015;11(7):1161-78.
Milan E, Fabbri M, Cenci S. Autophagy in Plasma Cell Ontogeny and Malignancy. J Clin Immunol. 2016 May; 36 Suppl 1:18-24. doi: 10.1007/s10875-016-0254-9. Epub 2016 Mar 16.
Milan E, Lazzari C, Anand S, Floriani I, Torri V, Sorlini C, Gregorc V, Bachi A. SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. J Proteomics. 2012; 76 Spec No.:91-101.
Oliva L, Orfanelli U, Resnati M, Raimondi A, Orsi A, Milan E, Palladini G, Milani P, Cerruti F, Cascio P, Casarini S, Rognoni P, Touvier T, Marcatti M, Ciceri F, Mangiacavalli S, Corso A, Merlini G, Cenci S. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. Blood. 2017 Apr 13;129(15):2132-2142.
Klionsky DJ, (…), Milan E, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 2016, Jan 2;12(1):1-222.
Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DL, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell. 2016 May 9;29(5):639-52. doi: 10.1016/j.ccell.2016.03.026. Epub 2016 Apr 28.
Pengo N, Scolari M, Oliva L, Milan E, Mainoldi F, Raimondi A, Fagioli C, Merlini A, Mariani E, Pasqualetto E, Orfanelli U, Ponzoni M, Sitia R, Casola S, and Cenci S. Plasma cells require autophagy for sustainable immunoglobulin production. Nat Immunol. 2013; 14(3):298-305
Cenci S, Oliva L, Cerruti F, Milan E, Bianchi G, Raule M, Mezghrani A, Pasqualetto E, Sitia R, Cascio P. Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. J Leukoc Biol. 2012;92(5):921-31